Pieris Pharmaceuticals, Inc. - Common Stock (NQ:PIRS)

13.60 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

March 04, 2022

According to Benzinga Pro data, during Q4, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $8.44 million. Earnings were up 42.36%, but Pieris Pharmaceuticals still reported...

Via Benzinga

Recap: Pieris Pharmaceuticals Q4 Earnings ↗

March 01, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

March 01, 2022

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST - Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year - Dosed first...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Thinking About Buying Stock In Pieris Pharmaceuticals, Baidu Or Cronos Group? ↗

February 28, 2022

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b...

Via Benzinga

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

February 23, 2022

BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Earnings Scheduled For November 2, 2021 ↗

November 02, 2021

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...

Via Benzinga

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa

January 14, 2022

BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402

January 03, 2022

BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

November 11, 2021

BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

November 08, 2021

BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 02, 2021

Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo...

Via Benzinga

Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 02, 2021

Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT - Dosing completed in part 1a of phase 2a study of PRS-060/AZD1402 - Dosing to begin this quarter in phase 2...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

Preview: Pieris Pharmaceuticals's Earnings ↗

November 01, 2021

Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement....

Via Benzinga

Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021

October 26, 2021

BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

3 Biotech Stocks to Watch Now ↗

October 12, 2021

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so. Most biotech stocks trade at low prices and...

Via Benzinga

Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer

October 06, 2021

BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 28, 2021

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 16, 2021

Gainers Stealth BioTherapeutics (NASDAQ:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 09, 2021

Gainers Impel NeuroPharma (NASDAQ:IMPL) shares increased by 22.16% to $20.29 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 1.1...

Via Benzinga

35 Stocks Moving In Thursday's Mid-Day Session ↗

September 09, 2021

Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE:...

Via Benzinga

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗

September 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

September 09, 2021

BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

48 Biggest Movers From Yesterday ↗

September 10, 2021

Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy...

Via Benzinga

Which Biotech Stock Will Shock the Market in 2022? ↗

August 27, 2021

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Via The Motley Fool

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab ↗

September 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...

Via Benzinga

Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

August 24, 2021

BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering ↗

September 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...

Via Benzinga

Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 04, 2021

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT - Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government...

From Pieris Pharmaceuticals, Inc.

Via AccessWire

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.